Joshua Bauml: The U.S. FDA approved our targeted therapy in combination with for NSCLC with specific EGFR mutations

Joshua Bauml, Vice President, Lung Cancer Disease Area Stronghold (DAS) Leader, shared a post on X:

“The U.S. FDA approved our targeted therapy in combination with chemotherapy for patients with previously treated NSCLC with specific EGFR mutations.

This milestone marks J&J Innovative Medicine’s third new indication in six months for this targeted therapy.”